Excellent news today from our portfolio company @Cerevance on the expansion of its Series B financing round, adding a further $20 million to the $45 million announced in April.

The additional proceeds will aid in the development of the company’s NETSseq platform which it is using to discover entirely novel drugs and therapeutic targets that could transform the treatment of patients with a range of CNS diseases, including #Alzheimer’s.

Read Cerevance’s full release here: https://cerevance.com/2020/07/21/cerevance-expands-series-b-financing-to-65-million/

#dementia